An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders

被引：9

作者：

Riccardo De Giorgi ^{[1
]}

Ana Ghenciulescu ^{[2
]}

Oliwia Dziwisz ^{[1
]}

Maxime Taquet ^{[1
]}

Amanda I. Adler ^{[1
]}

Ivan Koychev ^{[2
]}

Rachel Upthegrove ^{[3
]}

Marco Solmi ^{[1
]}

Robert McCutcheon ^{[4
]}

Toby Pillinger ^{[1
]}

Philip J. Cowen ^{[5
]}

Catherine J. Harmer ^{[6
]}

机构：

[1] Warneford Hospital,Department of Psychiatry, University of Oxford

[2] Warneford Hospital,Oxford Health NHS Foundation Trust

[3] John Radcliffe Hospital,Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford

[4] John Radcliffe Hospital,Oxford University Hospital NHS Foundation Trust

[5] University of Birmingham,Institute for Mental Health

[6] Birmingham Women’s and Children’s NHS Foundation Trust,Birmingham Early Intervention Service

[7] University of Ottawa,SCENCES Lab, Department of Psychiatry

[8] The Ottawa Hospital,Regional Centre for the Treatment of Eating Disorders and On Track: The Champlain First Episode Psychosis Program, Department of Mental Health

[9] Ottawa Hospital Research Institute (OHRI) Clinical Epidemiology Program University of Ottawa,Department of Child and Adolescent Psychiatry

[10] Charité Universitätsmedizin,Department of Psychosis Studies

[11] Institute of Psychiatry,undefined

[12] Psychology and Neuroscience,undefined

来源：

Nature Mental Health | 2025年 / 3卷 / 3期

关键词：

D O I：

10.1038/s44220-025-00390-x

中图分类号：

学科分类号：

摘要：

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are novel drugs approved for diabetes and obesity. They are acknowledged as a major scientific breakthrough. In addition to their metabolic effects, these medications act on other bodily systems involved in the physiopathology of various neurological and psychiatric disorders. Several stakeholders are calling for more research to investigate the repurposing potential of GLP-1RAs in cognitive and mental disorders, while others advocate for a better assessment of their safety profile from a neuropsychiatric perspective. In this Analysis, we searched for relevant literature on the effects of GLP-1RAs across a range of illnesses, gathering and describing the available pre-clinical and mechanistic (278 studies) and clinical (96 studies) evidence for cognitive disorders, substance-use disorders, psychotic disorders, mood and anxiety disorders, eating disorders, and others. By leveraging translational insights from these data, we consider potential implications for clinical practice and propose avenues for further research.

引用

页码：354 / 373

页数：19